Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elvire Pons

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Idcases|July 8, 2022
A fatal case associated with <i>Catabacter hongkongensis</i> bacteremia in lung cancer patient: A case reportValentin Mandin, Stéphane Corvec, Anne-Laure Chéné, et al.
Bulletin Du Cancer|January 31, 2022
[Re-visiting the Pronopall score ten years later: A multicenter retrospective study]Lucie Duval, You-Heng Lam, Elvire Pons-Tostivint, et al.
European Journal of Cancer Care|July 22, 2022
Treatment time interval in breast cancer: A population-based study on the impact of type and number of cancer centres attendedAmalia Martinez, Laetitia Daubisse-Marliac, Jean-Louis Lacaze, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2023
Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosisBenoit Nigen, Thomas Goronflot, Guillaume Herbreteau, et al.
Lung Cancer (Amsterdam, Netherlands)|July 11, 2024
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter studyElvire Pons-Tostivint, Remy Ezzedine, Thomas Goronflot, et al.
Clinical Lung Cancer|December 10, 2023
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) PatientsMarie Porte, Adrien Vaudron, Perrine Crequit, et al.
Bulletin Du Cancer|March 12, 2026
[Evaluation of the return-to-work rate in systemically treated non-small cell lung cancer patient]Marie Cap, Virginie Nael, Loan Mouézy, et al.
Clinical Lung Cancer|January 13, 2024
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung CancerLaurent Mathiot, Benoit Nigen, Thomas Goronflot, et al.
Cancer Immunology, Immunotherapy : CII|November 28, 2021
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabMathilde Bureau, Thierry Chatellier, Tanguy Perennec, et al.
Cancers|March 13, 2025
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer PatientsGuillaume Herbreteau, Marie Marcq, Chloé Sauzay, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Idcases|July 8, 2022
A fatal case associated with <i>Catabacter hongkongensis</i> bacteremia in lung cancer patient: A case reportValentin Mandin, Stéphane Corvec, Anne-Laure Chéné, et al.
Bulletin Du Cancer|January 31, 2022
[Re-visiting the Pronopall score ten years later: A multicenter retrospective study]Lucie Duval, You-Heng Lam, Elvire Pons-Tostivint, et al.
European Journal of Cancer Care|July 22, 2022
Treatment time interval in breast cancer: A population-based study on the impact of type and number of cancer centres attendedAmalia Martinez, Laetitia Daubisse-Marliac, Jean-Louis Lacaze, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2023
Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosisBenoit Nigen, Thomas Goronflot, Guillaume Herbreteau, et al.
Lung Cancer (Amsterdam, Netherlands)|July 11, 2024
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter studyElvire Pons-Tostivint, Remy Ezzedine, Thomas Goronflot, et al.
Clinical Lung Cancer|December 10, 2023
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) PatientsMarie Porte, Adrien Vaudron, Perrine Crequit, et al.
Bulletin Du Cancer|March 12, 2026
[Evaluation of the return-to-work rate in systemically treated non-small cell lung cancer patient]Marie Cap, Virginie Nael, Loan Mouézy, et al.
Clinical Lung Cancer|January 13, 2024
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung CancerLaurent Mathiot, Benoit Nigen, Thomas Goronflot, et al.
Cancer Immunology, Immunotherapy : CII|November 28, 2021
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabMathilde Bureau, Thierry Chatellier, Tanguy Perennec, et al.
Cancers|March 13, 2025
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer PatientsGuillaume Herbreteau, Marie Marcq, Chloé Sauzay, et al.
Pageof 6